AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
APGE has more than doubled off its 52-week low of $34.34 on elevated volume (2.0× avg).
Summary
Apogee Therapeutics has entered into a definitive agreement to be acquired by AbbVie Inc. for $135.11 per share in cash, valuing the company at approximately $10.9 billion.
Key Events · M&A and Partnerships · APGE
-
Definitive Merger Agreement
Apogee Therapeutics will be acquired by AbbVie Inc. for $135.11 per share in cash.
-
Significant Transaction Value
The acquisition is valued at approximately $10.9 billion, representing a substantial premium over the company's market capitalization.
-
Shareholder Support Secured
Key stockholders, including Fairmount Healthcare Fund II L.P. and Venrock Healthcare Capital Partners, have entered into voting agreements to support the merger.
-
Pipeline Expansion for Acquirer
AbbVie will gain Apogee's pipeline of immunology assets, including zumilokibart (APG777) for atopic dermatitis and APG273 for asthma.
Analysis · APGE · Life Sciences
Apogee Therapeutics has entered into a definitive merger agreement to be acquired by AbbVie Inc. for $135.11 per share in cash. This transaction, valued at approximately $10.9 billion, represents a substantial premium over Apogee's current market capitalization of $6.81 billion and its 52-week high, providing a highly favorable exit for shareholders. The deal confirms earlier market speculation and is supported by voting agreements from key stockholders, increasing the certainty of shareholder approval. The acquisition is expected to close in the third quarter of 2026, pending regulatory and remaining shareholder approvals.
At the time of this filing, APGE was trading at $133.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8B. The 52-week trading range was $34.34 to $95.32. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.